General Psychiatry

Getting Uncomfortable with Esketamine

January 13, 2020

Nolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA. Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The FDA approval of esketamine (Spravalto) left some unanswered questions, including suicide, addiction, withdrawal, neurotoxicity, and bladder inflammation. Nolan Williams addresses those risks and looks at where esketamine fits among other options like TMS and ECT. Dr. Williams directs the Interventional Psychiatry Clinical Research Program and Brain Stimulation Lab at Stanford University.

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials.

TMS: Deeper is not Better

January 13, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Two devices are available for transcranial magnetic stimulation (TMS). Neurostar came first with the figure-8 coil, which is now off-patent, while Brainsway’s H-coil which claims to reach deeper into the cerebral cortex. See how they compare in the first head-to-head controlled trial, undertaken without industry support.

In Brief: Antipsychotic Update

January 13, 2020

FDA Clears the Path for Magic Mushrooms. Psilocybin, the psychedelic compound in magic mushrooms, was fast-tracked by the FDA for major depression in November 2019.

Learning Objectives, Esketamine, TCPR, January 2020

January 13, 2020

After reading these articles, you should be able to…

CME Post-Test - Esketamine, TCPR, January 2020

January 13, 2020

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.

Highlights From This Issue

November 15, 2019

Quick hits on what you’ll find in this issue.

Adult-Onset ADHD

November 15, 2019

Michael Posternak, MD. and Chris Aiken, MD.

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Posternak and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

“I think I have ADHD” is a common complaint of psychiatric patients. Just about every disorder in the DSM can cause symptoms of ADHD, as can a host of medical problems. In this article we’ll show you how to sort through the possibilities.

Micronutrients in Mental Health

November 15, 2019

Julia Rucklidge, PhD

Julia Rucklidge, PhD

Professor, University of Canterbury, New Zealand Dr. Rucklidge has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Vitamins like B12 and folate have mental benefits, but what happens when you combine dozens of vitamins and nutrients in a single pill? We were skeptical, but the studies were positive, so we invited Julia Rucklidge to explain how these “micronutrients” work in ADHD, depression, autism, and general mental health.